PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD

Status Active, not recruiting

Clinical Trial Summary

This study will evaluate the efficacy and safety of pridopidine 45mg twice daily (BID) in patients with early stage manifest Huntington Disease (HD).

Clinical Trial Description

This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pridopidine 45 mg BID in patients with early stage HD. Eligible patients who completed the Main Study (65 to 78 weeks) will have the option to enroll into an open-label extension. ;

Study Design

Related Conditions & MeSH terms

Huntington Disease

Clinical Trial Details

NCT number	NCT04556656
Study type	Interventional
Source	Prilenia
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	October 16, 2020
Completion date	March 14, 2024

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03052712` - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies	N/A
Not yet recruiting	`NCT04429230` - Non-invasive Brain Stimulation in Huntington's Disease	N/A
Recruiting	`NCT05032196` - Study of WVE-003 in Patients With Huntington's Disease	Phase 1/Phase 2
Recruiting	`NCT03599076` - Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease
Terminated	`NCT04617860` - Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease	Phase 1/Phase 2
Completed	`NCT05748288` - Development of the Virtual Unified Huntington's Disease Rating Scale
Not yet recruiting	`NCT05360082` - Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD.
Not yet recruiting	`NCT04370470` - Development of Assessments for Later Stage HD
Recruiting	`NCT01834053` - Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea.	Phase 1/Phase 2
Completed	`NCT01357681` - Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)	Phase 2
Completed	`NCT01458470` - A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease	Phase 2
Completed	`NCT00980694` - Bioavailability of Ubiquinol in Huntington Disease	Phase 1
Completed	`NCT00146211` - TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease	Phase 3
Recruiting	`NCT01412125` - Study of Biomarkers That Predict the Evolution of Huntington's Disease	N/A
Completed	`NCT00075140` - Family Health After Predictive Huntington Disease (HD) Testing	Phase 3
Recruiting	`NCT04818060` - Preparing for Prevention of Huntington's Disease (PREVENT-HD)
Active, not recruiting	`NCT04698551` - NIPD on cffDNA for Triplet Repeat Diseases
Not yet recruiting	`NCT04301726` - Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD	Phase 1
Completed	`NCT03421327` - Genetic Risk: Whether, When, and How to Tell Adolescents
Recruiting	`NCT03296176` - Metabolomic Study in Huntington's Disease (METABO-HD)	N/A